Lexmond A - Search Results

1

Drug Delivery Devices for Inhaled Medicines.

Lexmond A, Forbes B. Lexmond A, et al. Handb Exp Pharmacol. 2017;237:265-280. doi: 10.1007/164_2016_67. Handb Exp Pharmacol. 2017. PMID: 27812896 Review.

2

A novel method for studying airway hyperresponsiveness in allergic guinea pigs in vivo using the PreciseInhale system for delivery of dry powder aerosols.

Lexmond AJ, Keir S, Terakosolphan W, Page CP, Forbes B. Lexmond AJ, et al. Drug Deliv Transl Res. 2018 Jun;8(3):760-769. doi: 10.1007/s13346-018-0490-z. Drug Deliv Transl Res. 2018. PMID: 29468423 Free PMC article.

3

Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs.

Lexmond AJ, Singh D, Frijlink HW, Clarke GW, Page CP, Forbes B, van den Berge M. Lexmond AJ, et al. Pulm Pharmacol Ther. 2018 Apr;49:27-35. doi: 10.1016/j.pupt.2018.01.004. Epub 2018 Jan 10. Pulm Pharmacol Ther. 2018. PMID: 29331645 Free article. Review.

4

Devices and formulations for pulmonary vaccination.

Tonnis WF, Lexmond AJ, Frijlink HW, de Boer AH, Hinrichs WL. Tonnis WF, et al. Expert Opin Drug Deliv. 2013 Oct;10(10):1383-97. doi: 10.1517/17425247.2013.810622. Epub 2013 Jun 21. Expert Opin Drug Deliv. 2013. PMID: 23786408 Review.

5

Challenging the two-minute tidal breathing challenge test.

Lexmond AJ, Hagedoorn P, Frijlink HW, de Boer AH. Lexmond AJ, et al. J Aerosol Med Pulm Drug Deliv. 2013 Dec;26(6):380-6. doi: 10.1089/jamp.2012.1021. Epub 2013 Mar 19. J Aerosol Med Pulm Drug Deliv. 2013. PMID: 23509936

6

Adenosine dry powder inhalation for bronchial challenge testing, part 1: inhaler and formulation development and in vitro performance testing.

Lexmond AJ, Hagedoorn P, van der Wiel E, Ten Hacken NH, Frijlink HW, de Boer AH. Lexmond AJ, et al. Eur J Pharm Biopharm. 2014 Jan;86(1):105-14. doi: 10.1016/j.ejpb.2013.06.027. Epub 2013 Oct 17. Eur J Pharm Biopharm. 2014. PMID: 24140941

7

New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation.

Grasmeijer F, Lexmond AJ, van den Noort M, Hagedoorn P, Hickey AJ, Frijlink HW, de Boer AH. Grasmeijer F, et al. PLoS One. 2014 Jan 28;9(1):e87825. doi: 10.1371/journal.pone.0087825. eCollection 2014. PLoS One. 2014. PMID: 24489969 Free PMC article.

8

Adenosine dry powder inhalation for bronchial challenge testing, part 2: proof of concept in asthmatic subjects.

Lexmond AJ, van der Wiel E, Hagedoorn P, Bult W, Frijlink HW, ten Hacken NH, de Boer AH. Lexmond AJ, et al. Eur J Pharm Biopharm. 2014 Sep;88(1):148-52. doi: 10.1016/j.ejpb.2014.04.008. Epub 2014 Apr 26. Eur J Pharm Biopharm. 2014. PMID: 24780441

9

Effect of inhaler design variables on paediatric use of dry powder inhalers.

Lexmond AJ, Kruizinga TJ, Hagedoorn P, Rottier BL, Frijlink HW, de Boer AH. Lexmond AJ, et al. PLoS One. 2014 Jun 5;9(6):e99304. doi: 10.1371/journal.pone.0099304. eCollection 2014. PLoS One. 2014. PMID: 24901338 Free PMC article.

10

Prerequisites for a dry powder inhaler for children with cystic fibrosis.

Lexmond AJ, Hagedoorn P, Frijlink HW, Rottier BL, de Boer AH. Lexmond AJ, et al. PLoS One. 2017 Aug 11;12(8):e0183130. doi: 10.1371/journal.pone.0183130. eCollection 2017. PLoS One. 2017. PMID: 28800360 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page